Mission Bio launched the company’s Pharma Assay Development (PAD) service, enabling its customers to obtain early access services based on the newest technologies as well as on existing products.
If you are not happy with the results below please do another search
50 search results for:
The tenth annual Pharmaceutical Innovation Index, released April 21, sees Eli Lilly top the industry for the first time. The Pharmaceutical Invention Index, a ranking of the industry’s best pipelines, rated Bristol Myers Squibb as No. 1.
European countries prepared on April 21 to resume deliveries of Johnson & Johnson’s Covid-19 vaccine and speed up the rollout after Europe’s drug regulator backed the shot.
India’s only domestically developed Covid-19 vaccine was found to be 78 percent effective in a second analysis of clinical trials done around the country, Covaxin’s makers said on April 21.
Swiss drugmaker Roche predicted on April 21 that demand for the company’s drugs would accelerate for the remainder of 2021, after first-quarter sales of Covid-19 tests offset a pandemic-influenced slump in its main pharmaceuticals business.
Japan’s government is considering a state of emergency for Tokyo and Osaka as new Covid-19 case numbers surge, broadcaster NHK reported on Wednesday, a move that would enable prefectural authorities to impose curbs to try to stop infections spreading.
Fujifilm Holdings Corp. said on April 21 the company started a new phase III trial in Japan of the drug Avigan for Covid-19, reviving hopes for a home-grown treatment for the virus.
Johnson & Johnson said on April 20 the company will resume rolling out its Covid-19 vaccine in Europe after the region’s medical regulator said the benefits of the shot outweigh the risk of very rare, potentially lethal blood clots.
Burlingame, California-based Humanigen reported positive data from the company’s Phase Ib ZUMA-19 trial of lenzilumab in patients treated with CAR-T in diffuse large B-cell lymphoma (DLBCL). Lenzilumab is being investigated for the drug compound’s ability to tamp down the hyper-immune response known as a cytokine storm.
One month after acquiring Five Prime Therapeutics and the company’s Phase III ready anti-FGFR2b antibody bemarituzumab for $1.9 billion, Amgen announced that the U.S. Food and Drug Administration awarded Breakthrough Therapy Designation to the asset as a first-line treatment for certain types of gastric cancer.